Wykorzystanie Internetu we wczesnym rozpoznawaniu akromegalii

• Authors: Bolanowski Marek
• Languages of publication: PL

Keywords

PL

diagnostyka; akromegalia; internet; terapia

• Publisher: Stowarzyszenie Przyjaciół Medycyny Rodzinnej i Lekarzy Rodzinnych
• Journal: Family Medicine & Primary Care Review
• Year: 2013
• Issue: 3
• Pages: 438-440

Contributors

author

Bolanowski Marek

References

• Melmed S. Medical progress: acromegaly. N Engl J Med 2006; 355: 2558–2573.
• Bolanowski M, Schopohl J, Marciniak M, et al. Acromegaly due to GHRH-secreting large bronchial carcinoid. Complete recovery following tumor surgery. Exp Clin Endocrinol Diabet 2002; 110: 188–192.
• Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999; 2: 29–41.
• Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management.Endocr Rev 2004; 25: 102–152.
• Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004; 89:667–674.
• Bolanowski M, Kałużny M, Jawiarczyk-Przybyłowska A. Somatotropinoma – akromegalia. W: Milewicz A, red. Endokrynologia kliniczna. T. 1. Wrocław: PTE; 2012: 157–162.
• Schneider HJ, Kosilek RP, Günther M, et al. A novel approach to the detection of acromegaly: accuracy of diagnostic by automatic face classification. J Clin Endocrinol Metab 2011; 96: 2074–2080.
• Akromegalia.pl – razem w walce z chorobą. www.akromegalia.pl.
• Rosario PW, Calsolari MR. Screening for acromegaly by application of a simple questionnaire evaluating the enlargement of extremities in adult patients seen at primary health care unit. Pituitary 2012; 15: 179–183.
• Colao A. The importance of presurgical somatostatin analogue therapy in acromegaly. Endokrynol Pol 2007; 58: 356–360.
• Bolanowski M, Bar-Andziak E, Kos-Kudła B, et al. Consensus statement of the Polish Society for Endocrinology: presusurgical somatostatin analogs therapy in acromegaly. Neuroendocrinol Lett 2008; 29: 59–62.
• Colao A, Auriemma RS, Rebora A, et al. Significant tumor shrinkage after 12 months of lanreotide Autogel 120 mg treatment given first-line in acromegaly. Clin Endocrinol 2009; 71: 237–245.
• van der Lely AJ, Biller BMK, Brue T, et al. Long-term safety of Pegvisomant in patients with acromegaly: comprehensive review of 1288 Subjects in Acrostudy. J Clin Endocrinol Metab 2012; 97: 1589–1597.
• Jawiarczyk A, Bolanowski M, Kałużny M, et al. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly. Neuro Endocrinol Lett 2008; 29: 571–576.
• Petersenn S, Schopohl J, Barkan A, et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly:a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 2010; 95: 2781–2789.
• Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly – a meta-analysis. J Clin Endocrinol Metab 2011; 96:1327–1335.
• Higham CE, Atkinson AB, Aylwin S, et al. Combination treatment with Cabergoline and low-dose Pegvisomant in active acromegaly:a prospective clinical trial. J Clin Endocrinol Metab 2012; 97: 1187–1193.